Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

The 11th St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level of estrogen receptor (ER) expression is considered sufficient to justify the use of endocrine adjuvant therapy in almost all patients. Overexpression or amplification of HER2 by standard criteria is an indication for anti-HER2 therapy for all but the very lowest risk invasive tumours. The corollary is that ER and HER2 must be reliably and accurately measured. Indications for cytotoxic adjuvant therapy were refined, acknowledging the role of risk factors with the caveat that risk per se is not a target. Proliferation markers, including those identified in multigene array analyses, were recognised as important in this regard. The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm.

[1]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[2]  M. Morrow,et al.  Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Dontu,et al.  S17 Breast cancer stem cells: Getting to treat the core , 2009 .

[4]  J. Sparano,et al.  TAILORx: trial assigning individualized options for treatment (Rx). , 2006, Clinical breast cancer.

[5]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Krauss,et al.  Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen , 2008, Clinical pharmacology and therapeutics.

[7]  R. Gelber,et al.  S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer , 2009 .

[8]  Tudor I. Oprea,et al.  Virtual and biomolecular screening converge on a selective agonist for GPR30 , 2006, Nature chemical biology.

[9]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[10]  I. Tannock,et al.  Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Cristofanilli The biological information obtainable from circulating tumor cells. , 2009, Breast.

[12]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[13]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Morrow,et al.  S28 Breast conservation and clear margins: Invasive or in situ involvement , 2009 .

[15]  M. Parotto,et al.  Pharyngo-laryngeal discomfort after breast surgery: comparison between orotracheal intubation and laryngeal mask. , 2009, Breast.

[16]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[17]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[18]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[19]  R. Lewensohn,et al.  An Autocrine VEGF / VEGFR 2 and p 38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells , 2008 .

[20]  T. Tuttle,et al.  Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Davidson,et al.  What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? , 2009, Current oncology reports.

[22]  A. Gown,et al.  Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Hayes Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer? , 2009, Breast.

[24]  A. LaCroix,et al.  S12 Five year results of a randomised placebo controlled trial of lasofoxifene (PEARL) on the incidence of ER positive breast cancer in postmenopausal women with osteoporosis , 2009 .

[25]  B. Jasani,et al.  Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. , 2008, American journal of clinical pathology.

[26]  V. Jordan,et al.  Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis , 2008, Breast Cancer Research.

[27]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[28]  F. Wenz,et al.  Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy , 2007, BMC Cancer.

[29]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[30]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[31]  L. Sarian,et al.  Relationship between body mass index, waist circumference and waist to hip ratio and the steroid hormone receptor status in breast carcinoma of pre- and postmenopausal women. , 2009, Breast.

[32]  A. Giobbie-Hurder,et al.  BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. , 2009 .

[33]  R. Kerbel S14 Modulation of angiogenesis: Clinical impact (in breast cancer) , 2009 .

[34]  D. Duranyıldız,et al.  Serum levels of angiogenic factors in early breast cancer remain close to normal. , 2009, Breast.

[35]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[36]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[37]  I. Smith Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions. , 2009, Breast.

[38]  Tudor I. Oprea,et al.  Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. , 2008, Annual review of physiology.

[39]  I. Smith,et al.  The follow-up of women at high risk for breast cancer relapse. , 2009, Breast.

[40]  J. Baselga,et al.  Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[42]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[43]  M. B. Walker,et al.  Immuno-modulatory effects of relaxation training and guided imagery in women with locally advanced breast cancer undergoing multimodality therapy: a randomised controlled trial. , 2009, Breast.

[44]  H. Kuerer,et al.  Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer , 2006, The British journal of surgery.

[45]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[46]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[47]  N. Davidson S35 Adjuvant therapies for premenopausal women with endocrine-responsive disease , 2009 .

[48]  M. J. van de Vijver,et al.  Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. , 2008, International journal of radiation oncology, biology, physics.

[49]  Breast conservation and sentinel lymph node biopsy after neoadjuvant systemic therapy. , 2009, Breast.

[50]  A. Giobbie-Hurder,et al.  Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  G. Viale Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment. , 2009, Breast.

[53]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[54]  J. Baselga S43 Review of new targeted drugs: Crawling towards the adjuvant setting , 2009 .

[55]  V. Galimberti S29 Axillary sentinel lymph node: How low can you go? , 2009 .

[56]  A. Goldhirsch,et al.  Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  E. Winer S39 Treatment of postmenopausal women with hormone responsive breast cancer , 2009 .

[58]  L. Brody S9 Current knowledge on genetic predispositions for breast cancer , 2009 .

[59]  A. Luini,et al.  Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  A. Goldhirsch,et al.  S15 The (last?) word about biomarkers for angiogenesis , 2009 .

[61]  J. Manson,et al.  Breast cancer after use of estrogen plus progestin in postmenopausal women. , 2009, The New England journal of medicine.

[62]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[64]  P. Ravdin S3 The changes in breast cancer incidence: A result of recent changes in hormone use by postmenopausal women? , 2009 .

[65]  A Cole,et al.  The changes. , 1991, Nursing times.

[66]  A. LaCroix,et al.  0033 Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women by baseline estradiol levels , 2009 .

[67]  Mitch Dowsett,et al.  Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[68]  F. B. Sørensen,et al.  High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[69]  Z. Hall Cancer , 1906, The Hospital.

[70]  J. Eeckhoute,et al.  Unique ERalpha cistromes control cell type-specific gene regulation. , 2008, Molecular endocrinology.

[71]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[72]  Marc Buyse,et al.  Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial , 2006, Nature Clinical Practice Oncology.

[73]  J. Forbes,et al.  Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93 , 2008, Breast Cancer Research and Treatment.

[74]  Cathy A. Andorfer,et al.  Adjuvant therapy of triple negative breast cancer , 2010, Breast Cancer Research and Treatment.

[75]  F. Roe Cancer Treatment , 1971, Nature.

[76]  M. Brown S6 Mining the steroid receptor cistrome for novel targets, biomarkers and risk alleles , 2009 .

[77]  V. Kataja,et al.  S24 Update of the FINHER trial based on 5 years of follow-up , 2009 .

[78]  K. Albain S40 Should genomic profiles be used to determine who should receive adjuvant chemotherapy , 2009 .

[79]  R. Lewensohn,et al.  An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells , 2008, Molecular Cancer Research.

[80]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[81]  M. Morrow,et al.  Presence of Lobular Carcinoma In Situ Does Not Increase Local Recurrence in Patients Treated with Breast-Conserving Therapy , 2008, Annals of Surgical Oncology.

[82]  P Kronqvist,et al.  Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index , 2006, Histopathology.

[83]  P. Fasching,et al.  Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. , 2009 .

[84]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[85]  E. D. de Vries,et al.  Molecular imaging of breast cancer. , 2009, Breast.

[86]  J. Klijn,et al.  Survival and prognostic factors in BRCA1-associated breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  E. D. de Vries,et al.  PET imaging of steroid receptor expression in breast and prostate cancer. , 2008, Current pharmaceutical design.

[88]  T. Julian,et al.  Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). , 2009, International journal of radiation oncology, biology, physics.

[89]  I. Smith S41 Targeting HER2 in the adjuvant setting: Dealing with new standards and open questions , 2009 .

[90]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[91]  Rachel Schiff,et al.  Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. , 2008, Endocrine reviews.

[92]  H. McLeod S18 Pharmacogenetics to drive breast cancer treatments , 2009 .

[93]  John R. Mackey,et al.  Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .

[94]  G. Kallergi,et al.  Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer , 2008, Clinical Cancer Research.

[95]  D. Hayes S37 Is there a standard type and duration of adjuvant chemotherapy , 2009 .

[96]  P. Dong,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.